Takeda kicks up GPCR work with Sosei Heptares, dishing out $26M to get GI drug discovery going
Takeda is joining the growing group of big-league players enlisting the GPCR experts at Sosei Heptares for drug design work.
Much like the Genentech deal unveiled days ago, the partnership with Takeda comes with $26 million in upfront and near-term milestones, with milestones adding up to $1.2 billion. Sosei Heptares will apply its technology — which generates both small molecules and antibodies based on stabilized GPCR structures — on a range of diseases, focusing initially on gut inflammation and motility disorders.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.